<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00862043</url>
  </required_header>
  <id_info>
    <org_study_id>FIBHGM-SIOVAC</org_study_id>
    <secondary_id>2007-007033-40</secondary_id>
    <secondary_id>EC07-90772</secondary_id>
    <nct_id>NCT00862043</nct_id>
  </id_info>
  <brief_title>Sildenafil for Secondary Pulmonary Hypertension Due to Valvular Disease</brief_title>
  <acronym>SIOVAC</acronym>
  <official_title>Sildenafil for Improving Outcomes After Valvular Correction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital General Universitario Gregorio Marañon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Salud Carlos III</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundación de Investigación en Red en Enfermedades Cardiovasculares</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital General Universitario Gregorio Marañon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the clinical efficacy of the mid-term treatment with
      sildenafil in patients with persistent moderate or severe pulmonary hypertension (PH) after a
      heart valve intervention.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase IV, prospective, multicenter, randomized, double-blind, placebo-controlled,
      academically funded clinical trial, with 6 months follow-up. A total of 354 patients will be
      recruited. Inclusion criteria are: 1) successful surgical or percutaneous repair of a cardiac
      valve at least one year before screening and 2) persistent moderate or severe PH, and 3)
      absence of any residual significant valvular lesion. Patients will be randomized 1:1 to
      received sildenafil 40 mg t.i.d. or placebo. The primary endpoint is a clinical composite
      score combining: all-cause mortality, hospital admission for heart failure, World Health
      Organization (WHO) functional class, and the patient global assessment score. Additional
      clinical and mechanistic secondary end-points are defined.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combined Outcome End-Point: all-cause mortality or hospital admission for heart failure, worsening of World Health Organization (WHO) functional class, or of the patient global assessment score</measure>
    <time_frame>Six months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to the sixth month in the in the six-minute walk test</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change on WHO functional capacity</measure>
    <time_frame>3 &amp; 6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular mortality</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospital admissions caused by or related to heart failure in each patient</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of progression/regression of tricuspid regurgitation by Doppler-echocardiography</measure>
    <time_frame>3 &amp; 6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change on right ventricular (RV) dimensions and function assessed by Doppler echocardiography</measure>
    <time_frame>3 &amp; 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change on RV volumes and function assessed by cardiac magnetic resonance</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change on the right catheterization hemodynamic parameters</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identify patients who are more likely to respond to therapy by pharmacogenetics analysis</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <condition>Valvular Heart Disease</condition>
  <arm_group>
    <arm_group_label>Sildenafil Citrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sildenafil Citrate 40 mg t.i.d. oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sildenafil-matched oral placebo 40 mg t.i.d</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil Citrate</intervention_name>
    <description>40 mg t.i.d.</description>
    <arm_group_label>Sildenafil Citrate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo t.i.d.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age at the date of selection ≥ 18 years

          -  Mean pulmonary pressure ≥ 30 mmHg, measured by a Swan-Ganz catheter placed in the
             pulmonary artery

          -  Heart valve intervention: surgical or percutaneous replacement, repair or dilatation
             performed at least one year before inclusion

          -  Stable clinical condition for at least one month, without hospital admissions for
             heart failure, and on appropriate and stable doses of conventional cardiovascular
             medications

        Exclusion Criteria:

          -  Requiring or likely to require the following medications: organic nitrates,
             alpha-blocker therapy, potent cytochrome P450 3A4 inhibitors (erythromycin,
             ketoconazole, cimetidine, HIV protease inhibitors such ritonavir and saquinavir)
             Patients who have suffered a myocardial infarction, stroke, or life-threatening
             arrhythmia within the last 6 months.

          -  Patients with resting hypotension, with systolic blood pressure &lt; 90 mmHg

          -  Patients with retinitis pigmentosa

          -  Anatomical deformation of the penis (such as angulation, cavernosal fibrosis or
             Peyronie's disease) or patients who have conditions which may predispose them to
             priapism (such as sickle cell anemia, multiple myeloma, or leukemia)

          -  Severe renal impairment with creatinine clearance &lt; 30 ml/min

          -  Significant hepatic dysfunction

          -  Prosthesis or valvular dysfunction with hemodynamic repercussion.

          -  Pregnant or breast-feeding women

          -  Patients unlikely to cooperate in the study or with inability or unwillingness to give
             informed consent

          -  Life expectancy less than 2 years due to non-cardiac disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Javier Bermejo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital General Universitario Gregorio Maranon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario Santiago de Compostela</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>A Coruña</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Alava</name>
      <address>
        <city>Vitoria</city>
        <state>Alava</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital German Trias y Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu y San Pau</name>
      <address>
        <city>Barcelona</city>
        <state>Barcelon</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Fundación de Alcorcón</name>
      <address>
        <city>Alcorcón</city>
        <state>Madrid</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Galdakao</name>
      <address>
        <city>Galdakao</city>
        <state>Vizcaya</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Juan Canalejo</name>
      <address>
        <city>La Coruna</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Leon</name>
      <address>
        <city>Leon</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Leonor</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Victoria</name>
      <address>
        <city>Malaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>Tenerife</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico de Valladolid</name>
      <address>
        <city>Valladolid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.mineco.gob.es</url>
    <description>Funding Agent</description>
  </link>
  <link>
    <url>http://www.isciii.es/htdocs/index.jsp</url>
    <description>Funding Agent</description>
  </link>
  <link>
    <url>http://www.redcardiovascular.com</url>
    <description>Cardiovascular Research Spanish National Network</description>
  </link>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2009</study_first_submitted>
  <study_first_submitted_qc>March 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2009</study_first_posted>
  <last_update_submitted>September 22, 2016</last_update_submitted>
  <last_update_submitted_qc>September 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Secondary Pulmonary Hypertension</keyword>
  <keyword>Valvular Heart Disease</keyword>
  <keyword>Phosphodiesterase-Inhibitors</keyword>
  <keyword>Sildenafil</keyword>
  <keyword>Outcomes Research</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

